Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.9 USD | +0.70% | +5.39% | -40.14% |
Apr. 29 | Truist Securities Cuts Teladoc's Price Target to $15 From $17, Maintains Hold Rating | MT |
Apr. 26 | UBS Adjusts Teladoc Price Target to $16 From $20, Maintains Neutral Rating | MT |
Financials (USD)
Sales 2024 * | 2.66B | Sales 2025 * | 2.76B | Capitalization | 2.19B |
---|---|---|---|---|---|
Net income 2024 * | -177M | Net income 2025 * | -110M | EV / Sales 2024 * | 0.93 x |
Net Debt 2024 * | 295M | Net Debt 2025 * | 44.72M | EV / Sales 2025 * | 0.81 x |
P/E ratio 2024 * |
-12.1
x | P/E ratio 2025 * |
-19.2
x | Employees | 5,208 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.22% |
Latest transcript on Teladoc Health, Inc.
1 day | +0.70% | ||
1 week | +5.39% | ||
Current month | +1.18% | ||
1 month | -1.75% | ||
3 months | -38.66% | ||
6 months | -23.76% | ||
Current year | -40.14% |
Managers | Title | Age | Since |
---|---|---|---|
Mala Murthy
CEO | Chief Executive Officer | 60 | 19-06-23 |
Jeff Nadler
CTO | Chief Tech/Sci/R&D Officer | - | 11-01-31 |
Nikolaos Nanis
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Snow
CHM | Chairman | 69 | 14-01-31 |
Sandra Fenwick
BRD | Director/Board Member | 73 | 20-11-18 |
David Shedlarz
BRD | Director/Board Member | 75 | 16-09-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.31% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 12.9 | +0.70% | 4,005,680 |
24-05-15 | 12.81 | +0.55% | 4,523,829 |
24-05-14 | 12.74 | +2.33% | 7,248,821 |
24-05-13 | 12.45 | +4.18% | 5,278,718 |
24-05-10 | 11.95 | -2.37% | 5,812,014 |
Delayed Quote Nyse, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.14% | 2.19B | |
+57.70% | 3.02B | |
+115.18% | 703M | |
+10.24% | 475M | |
-67.37% | 144M |
- Stock Market
- Equities
- TDOC Stock